Fundamentally New Therapeutic for the Treatment of Acinetobacter Baumannii Wound Infections

An increasing number of infections caused by the pathogenic and multi-drug-resistant bacterium Acinetobacter baumannii has been reported in patients at military medical facilities in which service members were injured in the Iraq/Kuwait region during Operation Iraqi Freedom and in Afghanistan during Operation Enduring Freedom. Due to their drug resistance, these infections have been difficult to treat. ConjuGon is developing a fundamentally new antibacterial technology that is able to kill virtually all Gram negative pathogens, regardless of their antibiotic resistance. We have extensive in vitro and in vivo data demonstrating the ability of this technology to effectively kill multi- and pan-resistant bacteria such as A. baumannii and Pseudomonas aeruginosa. ConjuGon is developing a topical antibacterial product, based on this technology, to be used to treat large wound infections such as those affecting military personnel.